Eton Pharmaceuticals, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Eton Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $270.00K.
- Eton Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-12-31 was $79.00K, a 11.24% decline year-over-year.
- Eton Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $0.00.
- Eton Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $169.00K, a 20.71% increase year-over-year.
- Eton Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $217.00K, a 12.50% decline from fiscal 2024.
- Eton Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $248.00K, a 8.30% increase from fiscal 2023.
- Eton Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $229.00K, a 33.92% increase from fiscal 2022.
- Eton Pharmaceuticals, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $171.00K, a 15.35% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $270.00K 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $217.00K 10-K · filed 2026-03-19 | |
| 2024-12-31 | $79.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $248.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2024-06-30 | $169.00K 10-Q · filed 2025-08-07 | |
| 2023-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $229.00K 10-K · filed 2026-03-19 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | |
| 2023-06-30 | $140.00K 10-Q · filed 2024-08-08 | |
| 2022-12-31 | $54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $171.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | |
| 2022-06-30 | $117.00K 10-Q · filed 2023-08-10 | |
| 2021-12-31 | $68.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $202.00K 10-K · filed 2024-03-14 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | |
| 2021-06-30 | $134.00K 10-Q · filed 2022-08-11 | |
| 2020-12-31 | $48.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $112.00K 10-K · filed 2023-03-16 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-16 | |
| 2020-06-30 | $64.00K 10-Q · filed 2021-08-16 | |
| 2019-12-31 | $111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $239.00K 10-K · filed 2022-03-16 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | |
| 2019-06-30 | $128.00K 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |